Sarah Cork
Subscribe to all posts by Sarah Cork
Among its various attempts to regulate drug prices, the Trump administration recently sought to force pharmaceutical advertisements to disclose the wholesale acquisition cost (WAC) of certain drugs. This effort was dealt a setback in June, when the D.C. Circuit found that the Department of Health and Human Services (HHS) overstepped its regulatory authority by compelling … Continue Reading
“Orphan” drug exclusivity, which is intended to reward drug companies’ investment in the development of certain drugs, might soon be harder to get—and keep. Over the past several months, Congress introduced two similar bills to amend a “loophole” in the Orphan Drug Act (ODA). On October 17, 2019, a bipartisan group of House members introduced … Continue Reading
HHS Can’t Force Disclosure of Drug Prices in Ads with “Blunderbuss” Rule
By Sarah Cork and Christopher J. Spadaro on Posted in Appellate, Health Care, Life Sciences
Bipartisan Congress Intensifies Efforts to Restrict Orphan Drug Exclusivity
By Sarah Cork on Posted in Federal Rules, Life Sciences
